Incretin Atlas › Trials › REDEFINE 9
REDEFINE 9
CagriSema · obesity
Design
- Molecule(s)
- CagriSema
- Population
- obesity
- Phase
- 3
- Duration
- 68 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CagriSema 1.0/1.0 mg | obesity | 68 | — | −21.0 % vs −2.0 % Δ −19.0 pp | — | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- CagriSema 1.0/1.0 mg · weight_eff · company announcement
CagriSema 1.0 mg/1.0 mg provided a weight reduction of 21.0% versus 2.0%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: REDEFINE 9. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-9/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.